Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compral is an over-the-counter analgesic combination product developed and marketed by Adcock Ingram Limited in South Africa. It is a small molecule combination drug containing three active ingredients: aspirin (400mg), paracetamol (100mg), and anhydrous caffeine (30mg). Aspirin acts as a non-steroidal anti-inflammatory drug (NSAID) by irreversibly inhibiting cyclooxygenase (COX) enzymes, providing anti-inflammatory and analgesic effects. Paracetamol (acetaminophen) provides additional analgesic and antipyretic effects, likely through central nervous system mechanisms involving the modulation of prostaglandin synthesis. Caffeine acts as a central nervous system stimulant and an adjuvant to enhance the analgesic efficacy of the other components. Compral is indicated for the symptomatic relief of mild to moderate pain, including headaches, dysmenorrhea, muscle and joint pain, dental pain, fever, and symptoms associated with colds or flu.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compral.